Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Guiyang Xintian Pharmaceutical Co.,Ltd. (002873.SZ)
Guiyang, CN
Guiyang Xintian Pharmaceutical Co.,Ltd. is a Chinese company dedicated to the research, development, production, and commercialization of traditional Chinese medicines (TCMs) for a wide range of ailments. Its product offerings include various pharmaceutical formulations such as hard capsules, gels, mixtures, granules, and tablets. These medicines are specifically designed to treat diverse medical conditions, including antitumor applications, gynecological issues, urinary tract problems, breast and thyroid disorders, blood-related illnesses, heat-related syndromes, oral health complaints, common colds, and cardiovascular diseases. The company was founded in 1995 and is headquartered in Guiyang, China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.46% | -6.65% | -11.30% | -17.75% | -18.75% | -12.20% | -3.22% | -41.54% | -3.97% | +9.42% | +9.42% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%-12.6% Q1'26: -7.5% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%-84.4% Q1'26: -14.0% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%+2.4% Q1'26: +13.3% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%+3.7% ★ Q1'26: +4.7% (vs Q1'25)
-
ROIC Biotechnology: -16.1%+1.6% ★ Q1'26: +1.3% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+10.5% Q1'26: -3.4% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×7.80× Q1'26: 18.64× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
985.00M
est.
|
969.84M
est: 1.32B (-26.6%)
|
1.09B
est: 1.38B (-21.4%)
|
953.98M
est: 1.38B (-31.1%)
|
857.55M
est: 1.56B (-45.2%)
|
749.72M
est: 631.00M (+18.8%)
|
669.00M
669.00M – 669.00M
+6.0% YoY
|
696.00M
696.00M – 696.00M
+4.0% YoY
|
| EBITDA |
143.10M
est.
|
156.66M
est: 192.06M (-18.4%)
|
157.88M
est: 201.06M (-21.5%)
|
125.68M
est: 201.06M (-37.5%)
|
110.65M
est: 205.44M (-46.1%)
|
66.96M
est: 82.89M (-19.2%)
|
87.88M
87.88M – 87.88M
+6.0% YoY
|
91.42M
91.42M – 91.42M
+4.0% YoY
|
| EBIT |
113.91M
est.
|
134.92M
est: 152.88M (-11.7%)
|
133.24M
est: 160.05M (-16.7%)
|
105.35M
est: 160.05M (-34.2%)
|
79.61M
est: 156.90M (-49.3%)
|
27.53M
est: 63.30M (-56.5%)
|
67.11M
67.11M – 67.11M
+6.0% YoY
|
69.82M
69.82M – 69.82M
+4.0% YoY
|
| Net Income |
96.78M
est.
|
100.61M
est: 129.04M (-22.0%)
|
111.52M
est: 127.78M (-12.7%)
|
80.87M
est: 127.78M (-36.7%)
|
52.32M
est: 107.15M (-51.2%)
|
9.11M
est: 21.92M (-58.4%)
|
36.53M
36.53M – 36.53M
+66.7% YoY
|
43.83M
43.83M – 43.83M
+20.0% YoY
|
| SGA |
490.12M
est.
|
606.18M
est: 657.81M (-7.8%)
|
673.99M
est: 688.66M (-2.1%)
|
589.02M
est: 688.66M (-14.5%)
|
513.64M
est: 835.62M (-38.5%)
|
157.68M
est: 337.13M (-53.2%)
|
357.43M
357.43M – 357.43M
+6.0% YoY
|
371.86M
371.86M – 371.86M
+4.0% YoY
|
| EPS |
0.44
est.
|
0.44
est: 0.59 (-24.9%)
|
0.48
est: 0.58 (-17.2%)
|
0.35
est: 0.58 (-39.7%)
|
0.24
est: 0.44 (-45.5%)
|
0.04
est: 0.09 (-58.4%)
|
0.15
0.15 – 0.15
+66.7% YoY
|
0.18
0.18 – 0.18
+20.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-28 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-27 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-26 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-25 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-22 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-21 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-20 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-19 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-18 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-15 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-14 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-13 | C+ | 2/5 | 1/5 | 3/5 | 3/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-12 | C+ | 2/5 | 1/5 | 3/5 | 3/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-11 | C+ | 2/5 | 1/5 | 2/5 | 3/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-29 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-28 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-27 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-24 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-23 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-22 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-21 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-20 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-17 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-16 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Da Lun Dong | GM & Chairman of the Board | — | male |
| Guangping Wang | Deputy GM, Director and Board Secretary | — | male |
| Jin Hua Wang | Vice Chairman & Deputy GM | — | male |
| Mao Chen Wei | Deputy General Manager | — | male |
| Zhihui Zeng | Chief Financial Officer & Accounting Supervisor | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 002873.SZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
